M-EZETIMIBE TABLET
Land: Canada
Språk: engelsk
Kilde: Health Canada
Preparatomtale
(SPC)
30-05-2023
Noen dokumenter for dette produktet er ikke tilgjengelig for øyeblikket, du kan sende en forespørsel til kundeservicen vår, og vi vil varsle deg så snart vi kan få dem.
Send forespørsel.
Send forespørsel.
Aktiv ingrediens:
EZETIMIBE
Tilgjengelig fra:
MANTRA PHARMA INC
ATC-kode:
C10AX09
INN (International Name):
EZETIMIBE
Dosering :
10MG
Legemiddelform:
TABLET
Sammensetning:
EZETIMIBE 10MG
Administreringsrute:
ORAL
Enheter i pakken:
100/500
Resept typen:
Prescription
Terapeutisk område:
CHOLESTEROL ABSORPTION INHIBITORS
Produkt oppsummering:
Active ingredient group (AIG) number: 0149164001; AHFS:
Autorisasjon status:
APPROVED
Autorisasjon dato:
2017-08-18
Preparatomtale
Page
1
of
30
PRODUCT MONOGRAPH
PR
M-EZETIMIBE
Ezetimibe Tablets, USP
10 mg
Cholesterol Absorption Inhibitor
Mantra Pharma Inc.,
1000 du Lux, suite 201
Brossard, Quebec
J4Y 0E3
Control # 275104
Date
of
Revision:
MAY
30, 2023
Page
2
of
30
TABLE OF CONTENT
Table of Content
.....................................................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................3
SUMMARY PRODUCT INFORMATION
...........................................................................................3
INDICATIONS AND CLINICAL USE
............................................................................................3
CONTRAINDICATIONS
.................................................................................................................4
WARNINGS AND PRECAUTIONS
................................................................................................4
ADVERSE REACTIONS
.................................................................................................................7
DRUG INTERACTIONS
................................................................................................................11
DOSAGE AND ADMINISTRATION
............................................................................................13
OVERDOSAGE
..............................................................................................................................14
ACTION AND CLINICAL PHARMACOLOGY
..........................................................................14
STORAGE AND STABILITY
........................................................................................................16
DOSAGE FORMS, COMPOSITION AND PACKAGING
...........................................................16
PART II: SCIENTIFIC INFORMATION
............................................................................................17
PHARMACEUTICAL INFORMATION
.......
Les hele dokumentet
